Literature DB >> 12634396

Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys.

Sallie R Permar1, Sherry A Klumpp, Keith G Mansfield, Woong-Ki Kim, Darci A Gorgone, Michelle A Lifton, Kenneth C Williams, Jörn E Schmitz, Keith A Reimann, Michael K Axthelm, Fernando P Polack, Diane E Griffin, Norman L Letvin.   

Abstract

The creation of an improved vaccine for global measles control will require an understanding of the immune mechanisms of measles virus containment. To assess the role of CD8(+) cytotoxic T lymphocytes in measles virus clearance, rhesus monkeys were depleted of CD8(+) lymphocytes by monoclonal anti-CD8 antibody infusion and challenged with wild-type measles virus. The CD8(+) lymphocyte-depleted animals exhibited a more extensive rash, higher viral loads at the peak of virus replication, and a longer duration of viremia than did the control antibody-treated animals. These findings indicate a central role for CD8(+) lymphocytes in the control of measles virus infections and the importance of eliciting a cell-mediated immune response in new measles vaccine strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12634396      PMCID: PMC150640          DOI: 10.1128/jvi.77.7.4396-4400.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Disturbances in gamma globulin synthesis as experiments of nature.

Authors:  R A GOOD; S J ZAK
Journal:  Pediatrics       Date:  1956-07       Impact factor: 7.124

2.  Global measles control and regional elimination, 1998-1999.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1999-12-17       Impact factor: 17.586

3.  Thymic aplasia with lymphopenia, plasma cells, and normal immunoglobulins. Relation to measles virus infection.

Authors:  A J Nahmias; D Griffith; C Salsbury; K Yoshida
Journal:  JAMA       Date:  1967-09-04       Impact factor: 56.272

4.  Measles as an index of immunological function.

Authors:  F M Burnet
Journal:  Lancet       Date:  1968-09-14       Impact factor: 79.321

5.  Cooperative measles vaccine field trial. I. Clinical efficacy.

Authors:  V F Guinee; D A Henderson; H L Casey; S T Wingo; D W Ruthig; T A Cockburn; T O Vinson; D C Calafiore; W Winkelstein; D T Karzon; M L Rathbun; E R Alexander; D R Peterson
Journal:  Pediatrics       Date:  1966-04       Impact factor: 7.124

6.  Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems.

Authors:  R Hofmann-Lehmann; R K Swenerton; V Liska; C M Leutenegger; H Lutz; H M McClure; R M Ruprecht
Journal:  AIDS Res Hum Retroviruses       Date:  2000-09-01       Impact factor: 2.205

7.  Measles rash. I. Light and electron microscopic study of skin eruptions.

Authors:  A Kimura; K Tosaka; T Nakao
Journal:  Arch Virol       Date:  1975       Impact factor: 2.574

8.  Prolonged measles virus shedding in human immunodeficiency virus-infected children, detected by reverse transcriptase-polymerase chain reaction.

Authors:  S R Permar; W J Moss; J J Ryon; M Monze; F Cutts; T C Quinn; D E Griffin
Journal:  J Infect Dis       Date:  2001-01-18       Impact factor: 5.226

9.  Demonstration of HLA restricted killer cells in patients with acute measles.

Authors:  H W Kreth; V ter Meulen; G Eckert
Journal:  Med Microbiol Immunol       Date:  1979-01-24       Impact factor: 3.402

10.  Use of a radioimmune assay in detection of measles antibodies in cerebrospinal fluid and serum.

Authors:  R A Good
Journal:  Acta Neurol Scand Suppl       Date:  1977
View more
  42 in total

1.  The association of CD46, SLAM and CD209 cellular receptor gene SNPs with variations in measles vaccine-induced immune responses: a replication study and examination of novel polymorphisms.

Authors:  Inna G Ovsyannikova; Iana H Haralambieva; Robert A Vierkant; Megan M O'Byrne; Robert M Jacobson; Gregory A Poland
Journal:  Hum Hered       Date:  2011-11-11       Impact factor: 0.444

Review 2.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

Review 3.  Immune containment and consequences of measles virus infection in healthy and immunocompromised individuals.

Authors:  Sallie R Permar; Diane E Griffin; Norman L Letvin
Journal:  Clin Vaccine Immunol       Date:  2006-04

4.  Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques.

Authors:  Wen-Hsuan Lin; Diane E Griffin; Paul A Rota; Mark Papania; Stephen P Cape; David Bennett; Brian Quinn; Robert E Sievers; Charles Shermer; Kenneth Powell; Robert J Adams; Steven Godin; Scott Winston
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

Review 5.  Measles virus, immune control, and persistence.

Authors:  Diane E Griffin; Wen-Hsuan Lin; Chien-Hsiung Pan
Journal:  FEMS Microbiol Rev       Date:  2012-03-13       Impact factor: 16.408

6.  Prolonged persistence of measles virus RNA is characteristic of primary infection dynamics.

Authors:  Wen-Hsuan W Lin; Roger D Kouyos; Robert J Adams; Bryan T Grenfell; Diane E Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-07       Impact factor: 11.205

Review 7.  Biological feasibility of measles eradication.

Authors:  William J Moss; Peter Strebel
Journal:  J Infect Dis       Date:  2011-07       Impact factor: 5.226

8.  Measles immunometrics.

Authors:  Theodore C Pierson; Jonathan W Yewdell
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-30       Impact factor: 11.205

9.  Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques.

Authors:  Chien-Hsiung Pan; Nitya Nair; Robert J Adams; M Christine Zink; Eun-Young Lee; Fernando P Polack; Manmohan Singh; Derek T O'Hagan; Diane E Griffin
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

10.  CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.

Authors:  Koen K A Van Rompay; Raman P Singh; Bapi Pahar; Donald L Sodora; Casey Wingfield; Jonathan R Lawson; Marta L Marthas; Norbert Bischofberger
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.